Navigation Links
Pharmos Corporation Reports 2011 Second Quarter Results
Date:8/8/2011

uction of various facility related expenses as the Company continued to reduce overall facility costs.

General and administrative expenses for the first half of 2011 decreased by $86,046, or 13%, from $639,806 in 2010 to $553,760 in 2011. The primary reductions were a $47,000 reduction in consultant and professional fees, a $31,000 reduction in salaries and benefits and an $8,000 reduction in various facility related expenses. Accounting fees have decreased as there were higher accounting fees related to the filing of a Regulation statement on Form S-1 in 2010. Also professional fees have decreased as there were business development fees in 2010 related to a possible reverse merger candidate which eventually was not pursued. The decrease in payroll costs in 2011 reflects lower stock compensation costs and the elimination of an administrative position in 2010. The decrease in the facility related expenses were a combination of all expense items and overall was not a significant reduction.

About Pharmos Corporation Pharmos discovers and develops novel therapeutics to treat a range of indications, including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders.  The Company's lead products are the two enantiomers of tofisopam. S-tofisopam (levotofisopam) is being evaluated for the treatment of gout, but has not yet entered clinical trials in the US. R-tofisopam (dextofisopam) has been developed through Phase 2b for IBS in the US. There is a large unmet need for new therapeutic alternatives for the treatment of IBS, a chronic and sometimes debilitating condition that affects roughly 10-15% of U.S. adults, primarily women. Pharmos is seeking a partnership with another pharmaceutical company to further develop this promising compound for IBS. The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds, with
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
2. Pharmos Issues Business Update on Dextofisopam Trial and Financing
3. Pharmos Corporation Reports 2009 Third Quarter Results
4. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
5. Pharmos Corporation Reports 2010 Third Quarter Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... 2015 Global physiotherapy ... USD 24.7 billion by 2022, according to a ... prevalence of neurological and musculoskeletal disorders are expected ... forecast period. The presence of efficient and effective ... the technologies coupled with implementation of favorable government ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
(Date:8/3/2015)... ... 2015 , ... To date, many pharmaceutical and biotech companies ... benefits, allowing them to gain access to capabilities that cannot be found in-house, ... get access to innovation and ensure timely introduction of product into the market. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... largest online retailer of nutritional supplements, has officially opened the polls for ... awards in the following categories:, ,     Brand of the ...
(Date:8/3/2015)... ... 2015 , ... The art of preparing and cooking food comes naturally to ... young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she ... My Persian Kitchen with the world. , Since Americans tend to be undereducated about ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Ahjumawi Lava Springs, California’s northernmost and among its least visited State Parks. ... water aquifers, whose main outflow is at Ahjumawi Lava Springs, part of the ...
(Date:8/3/2015)... ... 2015 , ... From 2006-2017 the number of dental laboratories ... research compiled for the National Association of Dental Laboratories ( NADL ) by ... Labor Statistics. As the number of dental laboratories decreases, dentists will have fewer ...
Breaking Medicine News(10 mins):Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... by Television Week for providing "vital information" to ... television program that tells the compelling and inspirational stories of ... markets: Denver, CO; Albany, NY; Austin, TX; Salt Lake City, ... all, the program now airs on nearly 260 television stations ...
... Improve Your Heart Health Through Proper Oral Care WASHINGTON, ... throughout the U.S. will be making personal pledges to ... initiative and promote heart health awareness, WomenHeart has partnered ... campaign. Heart Promises will focus on empowering ...
... Was Financially Untenable -LOS ANGELES, Feb. 9 According ... explanations offered for the closing of the Motion Picture ... up, raising questions about the underlying reasons for displacing ... live out their lives at the facility.The story by ...
... to learn about Heart Failure-how to prevent it and to ... Week February 8-14, 2009 Heart Failure Society of ... Available at www.abouthf.org NEW YORK, ... for February 8-14. This is a time for ...
... 9 Global multiservice public relations,agency Waggener ... panel discussion,titled "Healthcare Communications in the Digital ... Environment." The presentation will take place on,Tuesday, ... company,s Washington, D.C., office and be,available via ...
... to Discuss Results - EXTON, Pa., Feb. 9 ... that its Phase 3 trial evaluating maribavir used as ... (SCT) patients did not achieve its primary endpoint. In ... between maribavir and placebo in reducing the rate of ...
Cached Medicine News:Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 2Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 3Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 4Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 5Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 6Health News:WomenHeart Celebrates American Heart Month With Heart Promises Campaign 2Health News:WomenHeart Celebrates American Heart Month With Heart Promises Campaign 3Health News:WomenHeart Celebrates American Heart Month With Heart Promises Campaign 4Health News:National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure 2Health News:National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure 3Health News:Healthcare Online Regulations Discussed in Live Event and Webcast Hosted by Waggener Edstrom Worldwide 2Health News:ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients 2Health News:ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients 3Health News:ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients 4Health News:ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients 5
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
... Light transmitted via fiber optic ... Keeler otoscopes have bright halogen ... visualization of aural canal. ... capability. Ring rheostat for ...
Durable, simple and easy to use. Lightweight, base can detach and be used as a penlight....
Pocket-sized instrument. All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheos...
Medicine Products: